19. On December 14, 2017, a BCPD took Patient 2 to a hospital for a Sexual
Assault Forensic Examination (SAFE). As part of the examination, a toxicology screen
was obtained, which revealed a positive finding of Temazepam. ’

Respondent's Medical Records of Patient 2

20. On December 11, 2017,° at or about 9:15 a.m., Patient 2 presented to the
Respondent with the chief complaint of “pain all over.” Several areas of the
Respondent's medical record are illegible; however, the legible areas show that the
Respondent's sole physical findings were LBP (lower back pain) and tender/sore thigh.
The Respondent documented that at 10:00 a.m. he injected Ketorolac’ (the milligram
strength is not legible) in Patient 2’s right buttock.’®

21. On December 11, 2017, at or about 6:00 p.m., Patient 2 returned to the
Respondent's office. The Respondent documented that at 6:00 p.m. he injected
Ketorolac (the milligram strength is not legible) in Patient 2’s left buttock. The
Respondent's treatment plan and discharge medication is not legible, other than a
prescription for Amoxicillin.

22. Patient 2 takes several different medications. On December 11, 2017, the
Respondent printed a “Drug Interaction Report” which he placed in Patient 2’s medical

record.

? Temazepam (brand name Restoril), a benzodiazepine, is used to treat anxiety and for the short-term
treatment of insomnia. Common side effects include excessive sleepiness.

5 The Board does not have the Respondent's medical records of care of Patient 2 prior to December 11,
2017.

° Ketorolac Tromethamine (brand name Toradol), a non-steroidal anti-inflammatory, is indicated for the
short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia
at the opioid level.

© The Respondent holds a dispensing permit which was issued by the Board on April 11, 2013 and will
expire on April 10, 2018. Previously, the Respondent held a dispensing permit from 2009 to 2014.

7
